Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 376

1.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.

PMID:
29998338
2.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Jun 21;55:117-122. doi: 10.1016/j.canep.2018.06.005. [Epub ahead of print]

PMID:
29936140
3.

Changes in Surgical Volume and Outcomes Over Time for Women Undergoing Hysterectomy for Endometrial Cancer.

Wright JD, Ruiz MP, Chen L, Gabor LR, Tergas AI, St Clair CM, Hou JY, Ananth CV, Neugut AI, Hershman DL.

Obstet Gynecol. 2018 Jul;132(1):59-69. doi: 10.1097/AOG.0000000000002691.

PMID:
29889759
4.

Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.

Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L.

J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721. [Epub ahead of print]

PMID:
29889605
5.

Utilization of Ovarian Transposition for Fertility Preservation among Young Women with Pelvic Malignancies Who Undergo Radiotherapy.

Selter J, Huang Y, Grossman Becht LC, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2018 Jun 5. pii: S0002-9378(18)30447-2. doi: 10.1016/j.ajog.2018.05.037. [Epub ahead of print] No abstract available.

PMID:
29883577
6.

Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia.

Accordino MK, Wright JD, Vasan S, Buono DL, Hu JC, Neugut AI, Hershman DL.

JAMA Oncol. 2018 Jul 1;4(7):996-998. doi: 10.1001/jamaoncol.2018.0818. No abstract available.

PMID:
29799974
7.

Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions.

Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2018 Jul;219(1):89.e1-89.e15. doi: 10.1016/j.ajog.2018.05.001. Epub 2018 May 8.

PMID:
29750957
8.

Trends in Use and Survival Associated With Fertility-Sparing Trachelectomy for Young Women With Early-Stage Cervical Cancer.

Cui RR, Chen L, Tergas AI, Hou JY, St Clair CM, Neugut AI, Ananth CV, Hershman DL, Wright JD.

Obstet Gynecol. 2018 Jun;131(6):1085-1094. doi: 10.1097/AOG.0000000000002613.

PMID:
29742670
9.

Outcomes of Hysterectomy Performed by Very Low-Volume Surgeons.

Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Obstet Gynecol. 2018 Jun;131(6):981-990. doi: 10.1097/AOG.0000000000002597.

PMID:
29742669
10.

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL.

Clin Transl Oncol. 2018 May 7. doi: 10.1007/s12094-018-1888-2. [Epub ahead of print]

PMID:
29736694
11.

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.

Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, Hershman DL, Blanke CD, Ramsey SD.

J Natl Cancer Inst. 2018 Jun 1;110(6):553-559. doi: 10.1093/jnci/djy064.

PMID:
29684151
12.

Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.

Kroenke CH, Hershman DL, Gomez SL, Adams SR, Eldridge EH, Kwan ML, Ergas IJ, Kubo A, Kushi LH.

Breast Cancer Res Treat. 2018 Aug;170(3):623-631. doi: 10.1007/s10549-018-4774-2. Epub 2018 Apr 18.

PMID:
29671113
13.

Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.

Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, Unger JM.

J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414. [Epub ahead of print]

PMID:
29584550
14.

Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma.

Gómez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Hershman DL, Wright JD.

Cancer Invest. 2018 Mar 16;36(3):190-198. doi: 10.1080/07357907.2018.1449212. Epub 2018 Mar 22.

PMID:
29565689
15.

Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer.

Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Jun;149(3):545-553. doi: 10.1016/j.ygyno.2018.03.048. Epub 2018 Mar 17.

PMID:
29559171
16.

Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.

Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx098.

PMID:
29546345
17.

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.

Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr.

J Natl Cancer Inst. 2018 Mar 9. doi: 10.1093/jnci/djy035. [Epub ahead of print]

PMID:
29534197
18.

Impact of hospital volume on racial disparities and outcomes for endometrial cancer.

Buskwofie A, Huang Y, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 May;149(2):329-336. doi: 10.1016/j.ygyno.2018.02.019. Epub 2018 Mar 2.

PMID:
29506862
19.

Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, Hershman DL, Hielscher AH.

Radiology. 2018 Jun;287(3):778-786. doi: 10.1148/radiol.2018161041. Epub 2018 Feb 12.

PMID:
29431574
20.

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Leng S, Lentzsch S, Shen Y, Tsai WY, Wright JD, Hershman DL, Neugut AI.

Leuk Lymphoma. 2018 Feb 2:1-5. doi: 10.1080/10428194.2018.1429605. [Epub ahead of print] No abstract available.

PMID:
29390929
21.

Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials.

Chavez-MacGregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL.

Cancer. 2018 Apr 15;124(8):1760-1769. doi: 10.1002/cncr.31241. Epub 2018 Jan 25.

PMID:
29370458
22.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS.

J Natl Cancer Inst. 2018 Jun 1;110(6):669-676. doi: 10.1093/jnci/djx259.

PMID:
29361042
23.

Racial disparities in young women with endometrial cancer.

Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Mar;148(3):527-534. doi: 10.1016/j.ygyno.2017.12.032. Epub 2018 Jan 5.

PMID:
29307452
24.

Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors.

Freedman RA, Revette AC, Hershman DL, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL.

Biores Open Access. 2017 Dec 1;6(1):159-168. doi: 10.1089/biores.2017.0028. eCollection 2017.

25.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

PMID:
29278617
26.

Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ.

Richards CA, Rundle AG, Wright JD, Hershman DL.

JAMA Surg. 2018 Apr 1;153(4):344-351. doi: 10.1001/jamasurg.2017.5018.

PMID:
29214316
27.

Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.

Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Jan;148(1):19-27. doi: 10.1016/j.ygyno.2017.11.008. Epub 2017 Nov 16.

PMID:
29153542
28.

The modified frailty index and 30-day adverse events in oncologic neurosurgery.

Youngerman BE, Neugut AI, Yang J, Hershman DL, Wright JD, Bruce JN.

J Neurooncol. 2018 Jan;136(1):197-206. doi: 10.1007/s11060-017-2644-0. Epub 2017 Nov 14.

PMID:
29139096
29.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd.

J Clin Oncol. 2018 Feb 1;36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 Nov 14.

30.

Cost of Care for the Initial Management of Ovarian Cancer.

Bercow AS, Chen L, Chatterjee S, Tergas AI, Hou JY, Burke WM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Obstet Gynecol. 2017 Dec;130(6):1269-1275. doi: 10.1097/AOG.0000000000002317.

PMID:
29112648
31.

Estimating global treatment toxicity burden from adverse-event data.

Lee SM, Hershman DL, Miao J, Zhong X, Unger JM, Cheung YKK.

Cancer. 2018 Feb 15;124(4):858-864. doi: 10.1002/cncr.31107. Epub 2017 Nov 7.

PMID:
29112232
32.

American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action.

Ligibel JA, Alfano CM, Hershman DL, Merrill JK, Basen-Engquist K, Bloomgarden ZT, Demark-Wahnefried W, Dixon S, Hassink SG, Jakicic JM, Morton JM, Okwuosa TM, Powell-Wiley TM, Rothberg AE, Stephens M, Streett SE, Wild RA, Westman EA, Williams RJ, Wollins DS, Hudis CA.

Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S34-S39. doi: 10.1002/oby.21987.

PMID:
29086516
33.

Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms.

Malone H, Cloney M, Yang J, Hershman DL, Wright JD, Neugut AI, Bruce JN.

Neurosurgery. 2017 Aug 1. doi: 10.1093/neuros/nyx354. [Epub ahead of print]

PMID:
28973498
34.

National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery.

Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Int J Gynecol Cancer. 2018 Jan;28(1):19-25. doi: 10.1097/IGC.0000000000001132.

PMID:
28953134
35.

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ.

NPJ Breast Cancer. 2017 Sep 21;3:37. doi: 10.1038/s41523-017-0040-8. eCollection 2017. Review.

36.

All-cause mortality in young women with endometrial cancer receiving progesterone therapy.

Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2017 Dec;217(6):669.e1-669.e13. doi: 10.1016/j.ajog.2017.08.007. Epub 2017 Aug 24.

PMID:
28844824
37.

Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer.

Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, Hershman DL.

Obstet Gynecol. 2017 Sep;130(3):545-553. doi: 10.1097/AOG.0000000000002164.

PMID:
28796677
38.

Association between survival time with metastatic breast cancer and aggressive end-of-life care.

Accordino MK, Wright JD, Vasan S, Neugut AI, Gross T, Hillyer GC, Hershman DL.

Breast Cancer Res Treat. 2017 Nov;166(2):549-558. doi: 10.1007/s10549-017-4420-4. Epub 2017 Jul 27.

39.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

40.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

41.

Trends in end-of-life care and health care spending in women with uterine cancer.

Margolis B, Chen L, Accordino MK, Clarke Hillyer G, Hou JY, Tergas AI, Burke WM, Neugut AI, Ananth CV, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2017 Oct;217(4):434.e1-434.e10. doi: 10.1016/j.ajog.2017.07.006. Epub 2017 Jul 11.

PMID:
28709581
42.

Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib.

Lee SM, Zhang Y, Minasian LM, Unger JM, Hershman DL.

Cancer Invest. 2017 Aug 9;35(7):484-489. doi: 10.1080/07357907.2017.1340479. Epub 2017 Jul 10.

PMID:
28692317
43.
44.

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS.

NPJ Breast Cancer. 2017 May 19;3:20. doi: 10.1038/s41523-017-0021-y. eCollection 2017.

45.

Patterns of Specialty-Based Referral and Perioperative Outcomes for Women With Endometrial Cancer Undergoing Hysterectomy.

Wright JD, Chen L, Gabor L, Burke WM, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL.

Obstet Gynecol. 2017 Jul;130(1):81-90. doi: 10.1097/AOG.0000000000002100.

46.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.

Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ; From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups.

Breast Cancer Res Treat. 2017 Jul;164(2):371-378. doi: 10.1007/s10549-017-4265-x. Epub 2017 Apr 26.

47.

Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.

Bian J, Chen B, Hershman DL, Marks N, Norris L, Schulz R, Bennett CL.

J Clin Oncol. 2017 Jun 10;35(17):1945-1951. doi: 10.1200/JCO.2017.72.6273. Epub 2017 Apr 25.

48.

Characterizing 18 Years of the Death With Dignity Act in Oregon.

Blanke C, LeBlanc M, Hershman D, Ellis L, Meyskens F.

JAMA Oncol. 2017 Oct 1;3(10):1403-1406. doi: 10.1001/jamaoncol.2017.0243.

49.

Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.

Kwan ML, Roh JM, Laurent CA, Lee J, Tang L, Hershman D, Kushi LH, Yao S.

Cancer Causes Control. 2017 Jun;28(6):557-562. doi: 10.1007/s10552-017-0888-9. Epub 2017 Mar 27.

50.

Utility of radiation therapy for early-stage uterine papillary serous carcinoma.

Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2017 May;145(2):269-276. doi: 10.1016/j.ygyno.2017.03.003. Epub 2017 Mar 23.

PMID:
28343693

Supplemental Content

Loading ...
Support Center